好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Factors associated with Freezing of Gait in Parkinson's Disease: A multi-centric Mexican cohort
Movement Disorders
P14 - Poster Session 14 (8:00 AM-9:00 AM)
3-007

To identify demographic and clinical factors associated with freezing of gait (FoG) in a multi-centric Mexican Parkinson’s disease (PD) cohort.

FoG is common in PD with a prevalence of 54.8%. FoG represents a disabling phenomenon with a decay in patient’s quality of life. It also represents a risk factor for falls, fractures, and loss of independence. Identifying factors associated with FoG aids development of early intervention strategies.

An epidemiological, observational, cross-sectional, comparative, and analytical study was designed using the multi-centric PD cohort of the PSG-Mexico 2017-2018. A total of 306 patients were included. A univariate analysis was used to find associations between clinical and demographic variables and the presence of FoG (MDS-UPDRS items 2.13 and 3.11). Significantly associated variables were used to construct a multivariate regression model to determine predictive factors.

28.1% (86/306) reported symptoms of FoG. Motor PD subtypes: PIGD-PD (OR=12.31, p=.001) and TD (OR=0.06, p=.001), use of levodopa (OR=2.74, p=.015), use of dopamine agonists (OR=3.46, p=.06), use of pramipexole or rotigotine (OR=12.41, p=.001), use of COMT inhibitors (OR=5.425, p=.009), presence of hallucinations (OR=1.94, p=.03), apathy (OR=2.55, p=.004), sleeping problems (OR=1.74, p=.03), drooling (OR=4.36, p=<.001), and “off” painful dystonia (OR=7.21, p=.01) were significantly associated with FoG.

 

Multivariate analysis proved that PIGD (OR=20.1, p=<.0001), TD (OR=4.8, p=.02), drooling (OR=3.34, p=.004), disease duration (OR=1.11, p=.002), and severity of symptoms (OR=1.055, p=<.0001), were significant predictors for the presence of symptoms of FoG. Absence of symptoms of cognitive impairment showed to be a protective factor (OR= -1.054, p=.004). The model showed an accuracy 80.7%, sensitivity 71.4%, specificity 83.1%, PPV 52.3%, and NPV 91.8%.  

Prevalence and associated factors with FoG are similar to previously reported data. Our results suggest that motor subtype, disease duration, severity of disease predict patients at risk of FoG. A previously non-reported factor appeared to be “drooling”.

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Antonio Anaya-Escamilla, MD (CHRISTUS MUGUERZA Hospital Sur) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Mayela D. Rodriguez Violante, MD (Instituto Nacional de Neurología y Neurocirugía) Dr. Rodriguez Violante has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. Dr. Rodriguez Violante has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sandoz Novartis. Dr. Rodriguez Violante has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zydus. The institution of Dr. Rodriguez Violante has received research support from LARGE-PD.
Daniel Martinez-Ramirez, MD (Oncare) Dr. Martinez-Ramirez has nothing to disclose.